AU2021248653B2 - Reducing or inhibiting ocular damage by hyaluronidase administration - Google Patents

Reducing or inhibiting ocular damage by hyaluronidase administration Download PDF

Info

Publication number
AU2021248653B2
AU2021248653B2 AU2021248653A AU2021248653A AU2021248653B2 AU 2021248653 B2 AU2021248653 B2 AU 2021248653B2 AU 2021248653 A AU2021248653 A AU 2021248653A AU 2021248653 A AU2021248653 A AU 2021248653A AU 2021248653 B2 AU2021248653 B2 AU 2021248653B2
Authority
AU
Australia
Prior art keywords
minutes
hyaluronidase
composition
eye
hyaluronic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021248653A
Other languages
English (en)
Other versions
AU2021248653A1 (en
Inventor
Steve YOELIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med Progress LLC
Original Assignee
Med Progress LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Progress LLC filed Critical Med Progress LLC
Publication of AU2021248653A1 publication Critical patent/AU2021248653A1/en
Application granted granted Critical
Publication of AU2021248653B2 publication Critical patent/AU2021248653B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
AU2021248653A 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration Active AU2021248653B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
US63/004,444 2020-04-02
PCT/US2021/025668 WO2021203062A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Publications (2)

Publication Number Publication Date
AU2021248653A1 AU2021248653A1 (en) 2022-12-01
AU2021248653B2 true AU2021248653B2 (en) 2024-05-02

Family

ID=77921064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021248653A Active AU2021248653B2 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Country Status (11)

Country Link
US (1) US11878051B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125928A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521059A (cg-RX-API-DMAC7.html)
KR (1) KR20230005198A (cg-RX-API-DMAC7.html)
CN (1) CN115697348A (cg-RX-API-DMAC7.html)
AU (1) AU2021248653B2 (cg-RX-API-DMAC7.html)
CA (1) CA3174498A1 (cg-RX-API-DMAC7.html)
IL (1) IL296979A (cg-RX-API-DMAC7.html)
MX (1) MX2022012426A (cg-RX-API-DMAC7.html)
WO (1) WO2021203062A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003755A (es) * 2021-09-25 2024-04-15 Med Progress Llc Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa.
KR102922198B1 (ko) * 2022-04-25 2026-02-03 주식회사 메디팹 조직 수복용 생체재료의 분해 또는 교정용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
KR100566451B1 (ko) * 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DeLorenzi C.: "Discussion: Assessing Retrobulbar Hyaluronidase as a Treatment for Filler-Induced Blindness in a Cadaver Model", 2019, Plastic and Reconstructive Surgery, vol. 144, issue 2, pages 321-324, DOI: 10.1097/PRS.0000000000005861 *
Hartman, RR, & Kompella, UB, "Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery", 2018, J Ocul Pharmacol Ther., vol. 34, no. 1-2, pages 141-153 *
Hwang C.J. & Perry J.D.: "Effectiveness of Retrobulbar Hyaluronidase Injection in an Iatrogenic Blindness Rabbit Model Using Hyaluronic Acid Filler Injection", 2020, Plastic and Reconstructive Surgery, vol. 145, issue 3, pages 658e-669e *
Lee W. et al: "Reply: Effectiveness of Retrobulbar Hyaluronidase Injection in an Iatrogenic Blindness Rabbit Model Using Hyaluronic Acid Filler Injection", 2020, Plastic and Reconstructive Surgery, vol. 145, issue 3, pages 659e-661e *
Lee, W et al., "Effectiveness of Retrobulbar Hyaluronidase Injection in an Iatrogenic Blindness Rabbit Model Using Hyaluronic Acid Filler Injection", 2019, Plast reconstr surg., vol. 144, no. 1, pages 137-143 *
Zhu G-Z. et al: "Efficacy of Retrobulbar Hyaluronidase Injection for Vision Loss Resulting from Hyaluronic Acid Filler Embolization", 2017, Aesthetic Surgery Journal, vol. 38, issue 1, pages 12-22, DOI: 10.1093/asj/sjw216. *

Also Published As

Publication number Publication date
ZA202211833B (en) 2023-04-26
WO2021203062A1 (en) 2021-10-07
JP2026065067A (ja) 2026-04-14
MX2022012426A (es) 2023-01-11
CN115697348A (zh) 2023-02-03
CA3174498A1 (en) 2021-10-07
EP4125928A1 (en) 2023-02-08
US20210308234A1 (en) 2021-10-07
IL296979A (en) 2022-12-01
US11878051B2 (en) 2024-01-23
EP4125928A4 (en) 2024-06-12
JP2023521059A (ja) 2023-05-23
AU2021248653A1 (en) 2022-12-01
KR20230005198A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
Tseng et al. A randomized clinical trial of combined topical-intracameral anesthesia in cataract surgery
TW539560B (en) Ophthalmic drug delivery device
JP2026065067A (ja) ヒアルロニダーゼの投与による目の損傷の低減又は抑制
CN101107006B (zh) 治疗黏连性关节囊炎的方法
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
CRAIG BROWN et al. Use of dilute drug solutions for routine cycloplegia and mydriasis
US20250134966A1 (en) Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration
Alfayyadh et al. Advanced eales’ disease with neovascular glaucoma at first presentation
Loy et al. Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines
US20060034890A1 (en) Device for ocular delivery of active principles by the transpalpebral route
Murthy et al. Is there a role for retrobulbar hyaluronidase in hyaluronic acid vascular embolism related vision loss
SU1683740A1 (ru) Способ введени лекарственных веществ дл лечени заболеваний глаз
KR20100109549A (ko) Tgf-베타 3을 사용한 흉터의 억제
Bolaji-Alabi et al. CONSERVATIVE SURGICAL MANAGEMENT OF UNILATERAL TRAUMATIC PROPTOSIS IN AN EIGHT WEEK OLD BOERBOEL
Kangastupa A New Platform for Suprachoroidal Drug Delivery Using Standard Commercially Available Needles
RU2196556C2 (ru) Способ лечения органических и функциональных заболеваний сетчатки
Andrew Ingrowing toenails: an evaluation of two treatments
Hushaw Air Travel & IOLs
Cimberle et al. FEMCAT study evaluates value of femtosecond cataract surgery.
Mittendorf The Treatment of Detachment of the Retina
Welham et al. Squash ball to eye ball
Jayson Frozen shoulder: adhesive capsulitis
Porter Policeman's heel
HK1115295B (en) Methods for treating adhesive capsulitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)